A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Registrational; Therapeutic Use
  • Acronyms COAST
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 11 Oct 2016 Status changed from suspended to completed.
    • 14 Sep 2015 Planned End Date changed from 1 Sep 2021 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 14 Sep 2015 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2016 as repoted by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top